AN2 Therapeutics Inc., a company developing a once-daily treatment for people with chronic non-tuberculous mycobacterial lung disease, raised $69 million in an upsized IPO. The offering of 4.6 million shares (NASDAQ:ANTX), initially priced at $15 each, met a modest market reception, with shares rising to $15.40 by market close on March 25. The Menlo Park, Calif.-based company is developing epetraborole, a boron-containing small-molecule inhibitor of bacterial leucyl-tRNA synthetase, in-licensed from Anacor Pharmaceuticals Inc., now part of Pfizer Inc.
Zeta Surgical Inc. has raised $5.2 million in seed funding to improve the accuracy and safety of image-guided surgical procedures through its Zeta neurosurgical navigation platform. Zeta CEO Jose Maria Amich told BioWorld the funding will also advance a non-invasive ultrasound system for imaging the brain and help complete initial clinical studies for its FDA approvals application.
Digital health company Recora Inc. has surfaced from stealth mode with $20 million in series A funding to advance its comprehensive care management vision for heart disease patients.
Investors kicked in $45 million in a series C financing round for Podimetrics Inc., the maker of a device that provides early indication of developing diabetic foot ulcers. D1 Capital Partners led the round with new investor Medtech Convergence Fund and an undisclosed strategic investor. Polaris Partners and Scientific Health Developed returned for the series C, which brought the total raised by Podimetrics to date to more than $73 million.
Shouyao Holdings Co. Ltd. raised ¥1.48 billion ($233 million) in a listing on the Shanghai STAR Market to support the company’s ongoing clinical programs, led by a second-generation anaplastic lymphoma kinase inhibitor. Company shares (SHA:688197) debuted at ¥39.90, then fell 19.5% to close at ¥32.11 on March 23.
RSS
